Literature DB >> 7529536

A flow cytometric assay of CD34-positive cell populations in the bone marrow.

M Syrjälä1, T Ruutu, S E Jansson.   

Abstract

CD34+ BM cells form a heterogenous population of primitive stem cells and more mature progenitors committed to different lineages of differentiation. By combining CD45 expression with SSC, it is possible to separate immature cells from more differentiated BM cells, and, by three-colour flow cytometry, analyse the antigens expressed in various subsets of cells. In this paper we show that in the normal BM at least four distinct CD34+ cell populations can be identified by their different patterns of CD45 expression and SSC. The most immature CD34+ cell population (0.1% of the BM cellularity) lacked all signs of lineage commitment and was CD45RA negative and only weakly CD45 positive. With increasing expression of the CD45 antigens, a second CD34+ population (0.2% of the BM cellularity) was formed expressing mainly primitive lymphatic antigens. However, 30% of the cells co-expressed B-cell line antigens and myeloid antigens. Cells committed to the myeloid cell line lost B-cell line antigens, gained CD45 antigen expression and SSC and formed two CD34+ cell populations (0.2% and 0.1% of the BM cellularity, respectively) differing only with respect to the pattern of myeloid antigen expression and SSC characteristics. Similarly, differentiation along the lymphatic pathway implicated down-regulation of myeloid antigens, loss of the stem cell antigen and immature lymphatic antigens and gain of CD45 expression and mature lymphatic antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7529536     DOI: 10.1111/j.1365-2141.1994.tb05104.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.

Authors:  Chenyang Lu; Mohammad A Amin; David A Fox
Journal:  J Immunol       Date:  2020-01-01       Impact factor: 5.422

Review 2.  Gene therapy studies in a canine model of X-linked severe combined immunodeficiency.

Authors:  Peter J Felsburg; Suk See De Ravin; Harry L Malech; Brian P Sorrentino; Christopher Burtner; Hans-Peter Kiem
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-24       Impact factor: 5.032

3.  Myelo-enhancement by astragalus membranaceus in male albino rats with chemotherapy myelo-suppression. Histological and immunohistochemical study.

Authors:  Zeinab Mohamed Kamel Ismail; Noha Mohamed Afifi Amin; Mira Farouk Youssef Yacoub; Amira Mohamed Osman Mohamed
Journal:  Int J Stem Cells       Date:  2014-05       Impact factor: 2.500

4.  Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A.

Authors:  Jennifer E Adair; Devikha Chandrasekaran; Gabriella Sghia-Hughes; Kevin G Haworth; Ann E Woolfrey; Lauri M Burroughs; Grace Y Choi; Pamela S Becker; Hans-Peter Kiem
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

5.  Promoting therapeutic angiogenesis of focal cerebral ischemia using thrombospondin-4 (TSP4) gene-modified bone marrow stromal cells (BMSCs) in a rat model.

Authors:  Qian Zhang; Meiling Zhou; Xiangfeng Wu; Zhu Li; Bing Liu; Wenbin Gao; Jin Yue; Tao Liu
Journal:  J Transl Med       Date:  2019-04-04       Impact factor: 5.531

6.  Prolonged depletion of circulating CD4+ T lymphocytes and acute monocytosis after pantropic canine coronavirus infection in dogs.

Authors:  Mariarosaria Marinaro; Viviana Mari; Anna Lucia Bellacicco; Elvira Tarsitano; Gabriella Elia; Michele Losurdo; Giovanni Rezza; Canio Buonavoglia; Nicola Decaro
Journal:  Virus Res       Date:  2010-06-15       Impact factor: 3.303

Review 7.  CD13--not just a marker in leukemia typing.

Authors:  D Riemann; A Kehlen; J Langner
Journal:  Immunol Today       Date:  1999-02

8.  Sodium ferulate and n-butylidenephthalate combined with bone marrow stromal cells (BMSCs) improve the therapeutic effects of angiogenesis and neurogenesis after rat focal cerebral ischemia.

Authors:  Qian Zhang; Yonghua Zhao; Youhua Xu; Zhenwei Chen; Naiwei Liu; Chienchih Ke; Bowen Liu; Weikang Wu
Journal:  J Transl Med       Date:  2016-07-28       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.